-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 I4v/SQagx9/5EC9VS5xpaxJEYJe3/tA4CRy2VB6iZYfDkNAQGN9/ktbruhyOsE0D
 GNXlu4D1wR62GYNxY6VusA==

<SEC-DOCUMENT>0000719135-00-000004.txt : 20000329
<SEC-HEADER>0000719135-00-000004.hdr.sgml : 20000329
ACCESSION NUMBER:		0000719135-00-000004
CONFORMED SUBMISSION TYPE:	NT 10-K
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	19991231
FILED AS OF DATE:		20000328

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BOVIE MEDICAL CORP
		CENTRAL INDEX KEY:			0000719135
		STANDARD INDUSTRIAL CLASSIFICATION:	INDUSTRIAL ORGANIC CHEMICALS [2860]
		IRS NUMBER:				112644611
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		NT 10-K
		SEC ACT:		
		SEC FILE NUMBER:	000-12183
		FILM NUMBER:		581086

	BUSINESS ADDRESS:	
		STREET 1:		734 WALT WHITMAN ROAD
		CITY:			MELVILLE
		STATE:			NY
		ZIP:			11747
		BUSINESS PHONE:		5164215452

	MAIL ADDRESS:	
		STREET 1:		734 WALT WHITMAN ROAD
		CITY:			MELVILLE
		STATE:			NY
		ZIP:			11747

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AN CON GENETICS INC
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>NT 10-K
<SEQUENCE>1
<DESCRIPTION>10K EXTENSION
<TEXT>

                       SECURITIES AND EXCHANGE COMMISSION
                              WASHINGTON, DC 20549
                                  FORM 12B-25

                         COMMISSION FILE NUMBER 0-12183

                          NOTIFICATION OF LATE FILING

                       (Check One): XForm 10-K _Form 11-K

                        _Form 20-F Form 10-Q _Form N-SAR

                      For Period Ended : December 31,1999

                         Transition Report on Form 10-K
                         Transition Report on Form 10-Q
                         Transition Report on Form 20-F
                         Transition Report on Form N-SAR
                         Transition Report on Form 11-K

                        For the Transition Period Ended:


  Read attached instruction sheet before preparing form, please print or type.

    Nothing in this form shall be construed to imply that the commission has
                   verified any information contained herein.

 If the notification relates to a portion of the filing checked above, identify
                 the item(s) to which the notification relates:

                                     PART I
                             REGISTRANT INFORMATION

                  Full name of registrant BOVIE MEDICAL CORP.

                 Former name if applicable An-Con Genetics, Inc.
                     Address of principal executive offices
                        734 Walt Whitman Road, Suite 207
                               Melville, NY 11747

                                    PART II
                            RULE 12-b25: (b) and (c)

If the subject report could not be filed without  unreasonable effort or expense
and the  registrant  seeks  relief  pursuant to rule 12b-25 (b),  the  following
should be completed. (check appropriate box).

X(a) The reasons  described in reasonable  detail in Part III of this form could
not be eliminated without unreasonable effort or expense;

X(b) The subject annual report,  semi-annual report,  transition report, on Form
10-K,  20-F,  11-K or Form N-SAR,  or portion thereof will be filed on or before
the 15th  calendar  day,  following  the  prescribed  due date;  or the  subject
quarterly  report or transition  report on Form 10-Q, or portion thereof will be
filed on or before the fifth calendar day following the prescribed due date; and

  (c) The  accountant's  statement or other exhibit required by Rule 12b-25 (c)
has been attached if applicable.

                                    PART III
                                   NARRATIVE

State below in reasonable  detail the reasons why Form 10-K,  11-K,  20-F, 10-q,
N-SAR or the  transition  report  portion  thereof would not be filed within the
prescribed time period.

Additional time required for the filing of the 10KSB for the Year ended December
31, 1999 due to the time  required  to prepare  certain  documents,  analyze and
evaluate certain transactions.


                                    PART IV
                               OTHER INFORMATION

 (1) Name and telephone number of person to contact in regard to this
                                  notification

                                Andrew Makrides
                                     (Name)
                                  516 421-5452
                                  (Telephone)

(2) Have all other  periodic  reports  required  under section 13 or 15(d)of the
Securities  Exchange Act of 1934 or Section 30 of the Investment  Company Act of
1940  during  the  preceding  12  months  or for such  shorter  period  that the
registrant was required to file such report(s) been filed?  If the answer is no,
identify report(s).

             XYes        No

(3) Is it anticipated that any significant  change in results of operations from
the  corresponding  period for the last  fiscal  year will be  reflected  by the
earnings statement to be included in the subject report or portion thereof?
                Yes     XNo

If so: attach an explanation of the  anticipated  change,  both  narratively and
quantitatively,  and  , if  appropriate,  state  the  reasons  why a  reasonable
estimate of the results cannot be made.

                              BOVIE MEDICAL CORP.
                        (Name of Registrant as specified
                                  in Charter)

Has  caused  this  notification  to be signed on its  behalf by the  undersigned
thereunto duly authorized.

Date 3/28/00

By S/Andrew Makrides


President  Instruction.  The form may be signed by an  executive  officer of the
registrant or by any other duly authorized representative. The name and title of
the person signing the form shall by typed or printed beneath the signature.  If
the  statement  is  signed  on  behalf  of  the   registrant  by  an  authorized
representative,  (other than an executive officer), evidence shall be filed with
the form of the  representative's  authority to sign on behalf of the registrant
shall be filed with the form.


                                   ATTENTION

Intentional  misstatements  or omissions  of fact  constitute  Federal  criminal
violations (see 18 U.S.C. 1001).


GENERAL INSTRUCTIONS

1. This form is required by Rule 12b- 25 of the  General  Rules and  Regulations
under the Securities Exchange Act of 1934.

2. One signed  original and four  conformed  copies of this form and  amendments
thereto must be completed and filed with the Securities and Exchange Commission,
Washington,  DC 20549,  in  accordance  with Rule 0-3 of the  General  Rules and
Regulations  under the Act. The information  contained in or filed with the form
will be made a matter of the public record in the Commission files.

3. A manually signed copy of the form and amendments thereto shall be filed with
each  national  securities  exchange  on which  any class of  securities  of the
registrant is registered.

4.  Amendments to the  notifications  must also be filed on Form 12b-25 but need
not restate  information  that has been correctly  furnished.  The form shall be
clearly identified as an amended notification.

5. Electronic Filers. This form shall not be used by electronic filers unable to
timely file a report  solely due to  electronic  difficulties.  Filers unable to
submit a report  within  the  time  period  prescribed  due to  difficulties  in
electronic  filing  should comply with either Rule 201 or Rule 202 of Regulation
S-T or  apply  for an  adjustment  in  filing  date  pursuant  to  Rule  13(b)of
Regulation S-T.
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
